Clinical Trial Assessing 5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Anterior Resection Syndrome

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Male

Summary

Poor functional outcomes has been reported inevitably, and up to 90% of the patients have experienced bowel habit changes after sphincter-saving surgery for rectal cancer. But, currently there has been no specific treatment for ARS and symptom based empirical management is tried Recently, 5-HT3 receptor antagonists can be used for treatment of IBS-D, and has been revealed to be slowing the bowel movement and improving stool consistency and urgency.

We performed the clinical trial with using ramosetron (Irribow®) for the treatment of ARS

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Collaborator: Dong-A ST
• Treatments: Ramosetron

Criteria

Inclusion Criteria:

• The patients who undergo sphincter saving surgery for rectal cancer

Exclusion Criteria:

• recurred rectal cancer

• rectal cancer with distant metastasis

• permanent stoma formation

• postoperative concurrent chemoradiotherapy

• uncontrolled medical disease

• inflammatory bowel disease

• uncontrolled constipation

• preoperative incontinence (LARS score, more than 20)

• allergic to intervention drug